인벤테라

0007J0KOSDAQ자연과학 및 공학 연구개발업

49.8 / 100

Reference Date: 2026-07-24

Financial Score16.5 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Invenia is a biopharmaceutical company developing the 'Invinity™' polysaccharide-based nanotechnology platform to inhibit protein corona formation, enhance intrabody stability, and enable targeted drug delivery. The company focuses on addressing unmet medical needs through alternative MRI contrast agents and nano-medicines administered via oral or intra-articular injection methods.

Number of Employees

18people

Average Salary

78.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

4.12Industry Average 2.521.0Point

1.6x industry avg (risky)

ROE

-45.55Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

3.92Industry Average 7.315.0Point

Lower than industry avg (good)

Trend 3.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

0.0 / 4

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
인벤테라, KDDF 글로벌 RA 지원사업 선정...글로벌 사업화 속도
인벤테라의 차세대 MRCP 조영제 INV-003가 FDA IND 승인 및 글로벌 사업화를 가속화하는 KDDF 지원사업 선정으로 긍정적인 시장 반응 예상.
Positive
인벤테라, 경구용 MRCP 조영제 비임상 패키지 완성…임상 진입 본격화
인벤테라의 경구용 MRCP 조영제 'INV-003'의 임상 진입이 본격화되어 글로벌 시장 진출에 긍정적 영향을 미칠 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 7,480Won52-week high 35,25052-week low 7,030

1-month return0.0Point

1m -16.89% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0